Ultrasonic responsive antibacterial microbubble and preparation method thereof

By using mPEG-b-(PCL-co-PLA) copolymer and chitosan combined with tricalcium phosphate, ultrasonic responsive antibacterial microvesicles were prepared with high stability and good biocompatible, and the stability in vivo was solved. The problem of low and difficult drug release control has achieved effective antibacterial treatment.

CN118903412APending Publication Date: 2024-11-08CHARACTERISTIC MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY STRATEGIC SUPPORT FORCES
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410913294.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Ultrasonic-responsive antibacterial microvesicles have low stability in the body, difficulty in controlling drug release, and insufficient biosafety.

Method used

Using mPEG-b-(PCL-co-PLA) copolymer and chitosan as materials, combined with tricalcium phosphate, ultrasonic-responsive antibacterial microbubbles were prepared by emulsification and solvent evaporation preparation method to enhance their responsiveness under ultrasonic action. and biocompatibility.

Benefits of technology

It improves the structural stability of microvesicles and drug release efficiency, reduces the risk of immune response and toxicity, ensures effective release of drugs when needed, and enhances antibacterial effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an ultrasonic responsive antibacterial microbubble and a preparation method thereof. The preparation method comprises the following steps: (1) preparing an mPEG-b-(PCL-co-PLA) copolymer; (2) preparing an organic phase; (3) preparing an inner water phase; (4) preparing an external water phase; (5) mixing the internal water phase into the organic phase to prepare a W / O primary emulsion; (6) dispersing the W / O primary emulsion into an external water phase under a mechanical stirring condition to obtain W / O / W multiple emulsion, and preparing antibacterial microbubbles; and (7) injecting C3F8 gas into the antibacterial microbubbles to obtain the ultrasonic responsive antibacterial microbubbles. The ultrasonic-responsive antibacterial microbubbles prepared by the method have good structural stability, can be kept stable in an in-vivo environment and ensure that drugs can be effectively released when needed, and the addition of tricalcium phosphate enhances the responsiveness of the antibacterial microbubbles under the action of ultrasonic waves and improves the release efficiency of the drugs; meanwhile, the responsive antibacterial microbubbles prepared by the method disclosed by the invention also have good biocompatibility and safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biological antibacterial materials, and in particular to an ultrasonic responsive antibacterial microbubble and a preparation method thereof. Background Art

[0002] In recent years, with the continuous advancement of science and technology, ultrasound microbubble technology has been significantly developed, especially in the field of drug and gene delivery. Researchers have successfully transformed ultrasound microbubbles into an efficient drug or gene targeting delivery tool by designing and manufacturing microbubbles or other multifunctional acoustic particles that can carry drugs, genes or other therapeutic substances. These microbubbles can not only protect biologically unstable substances in the body, prevent them from being decomposed, and improve their stability in the body, but also effectively reduce the toxic side effects caused by systemic administration. Microbubbles carrying drugs, combined with ultrasound targeted microbubble destruction (UTMD) technology, have become an important means of targeted therapy and have been verified in many studies. Therapeutic substances can be encapsulated or integrated into microbubbles in a variety of ways, such as being encapsulated inside microbubbles, or integrated into the shell of microbubbles, or even directly adhered to the surface of microbubbles. In addition, microbubbles and drugs can be mixed and directly injected into the human body. When these microbubbles are irradiated with ultrasound close to their resonant frequency, they begin to oscillate, and as the ultrasound energy increases, the amplitude of the oscillation gradually increases, eventually leading to the rupture of the microbubbles, thereby achieving targeted release of drugs.

[0003] Under the action of ultrasound, microbubbles undergo repeated compression and expansion processes. When the ultrasound intensity reaches a certain critical value, the microbubbles will burst, instantly releasing the energy accumulated inside them, forming a strong shock wave or jet, and producing biological effects such as cavitation effect on the surrounding biological tissue cells. The presence of microbubbles actually lowers the threshold required for ultrasound to produce cavitation effect, thereby enhancing this effect. When microbubbles burst in a specific target area and under specific ultrasound energy irradiation, they can release the drugs they carry at a high local concentration. This characteristic makes microbubbles an efficient tool for drug delivery. By destroying microbubbles with ultrasound, its cavitation effect can expand the gap between capillary endothelial cells in the target area, increase cell membrane permeability, and even cause overflow holes in the cells. This effect greatly promotes the entry of drugs in microbubbles into the vascular gap and target cells, thereby increasing the concentration of drugs in the target tissue and enhancing their local therapeutic effect. At the same time, this method also reduces the toxic side effects of drugs on the whole body. UTMD (ultrasound-mediated microbubble destruction) technology is based on the above principle. It enhances the permeability of capillary walls and cell membranes in the target area by generating cavitation effect, thereby improving the efficiency of drug uptake by local tissue cells. At present, the application of responsive drug-loaded microbubbles has been widely expanded to the treatment field, especially in targeted treatments such as tumors, cardiovascular diseases and inflammatory diseases, showing great potential and development. Therefore, drug carriers based on ultrasound response provide new ideas and methods for the research of sustained-release treatment of anti-infective drugs.

[0004] Ultrasound-responsive antibacterial microbubbles are a new type of treatment that combines ultrasound technology and antibacterial therapy. This technology can be used to treat a variety of bacterial infections, including skin infections, bone infections, internal organ infections, etc. It is particularly suitable for infections that are difficult to treat with conventional methods, such as chronic infections associated with biofilms.

[0005] As an emerging technology, ultrasound-responsive antibacterial microbubbles have many potential advantages and application prospects. However, it also has some shortcomings:

[0006] Stability issues: Microbubbles may be affected by a variety of factors in the body, such as hemodynamics, temperature, pH value, etc., which may reduce their stability and make them prone to rupture or deformation. This will affect the circulation time of microbubbles in the body and their ability to reach the target site, thereby reducing the therapeutic effect.

[0007] Drug release control: Although ultrasound-responsive antibacterial microbubbles can achieve directional release of drugs under the action of ultrasound, the rate and amount of drug release are still difficult to accurately control. This may lead to insufficient or excessive drug concentration at the target site, affecting the therapeutic effect and possibly causing side effects.

[0008] Safety issues: Ultrasound-responsive antibacterial microbubbles interact with biological tissues in the body and may have potential biological toxicity or immune responses. Summary of the invention

[0009] Based on the problems existing in the background technology, the present invention provides an ultrasound-responsive antibacterial microbubble and a preparation method thereof. The ultrasound-responsive antibacterial microbubble prepared by the method of the present invention has good structural stability, can remain stable in the in vivo environment, and ensures that the drug can be effectively released when needed. The addition of tricalcium phosphate enhances the responsiveness of the antibacterial microbubble under the action of ultrasound and improves the release efficiency of the drug; at the same time, the responsive antibacterial microbubble prepared by the method of the present invention also has good biocompatibility and safety.

[0010] The present invention is implemented by the following technical solutions:

[0011] A method for preparing ultrasound-responsive antibacterial microbubbles comprises the following steps:

[0012] (1) mPEG-b-(PCL-co-PLA) copolymers were prepared using caprolactone and lactide as monomers and methoxy poly(ethylene glycol) as initiator;

[0013] (2) preparing the organic phase: dissolving the mPEG-b-(PCL-co-PLA) copolymer in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly;

[0014] (3) preparing the inner aqueous phase: dissolving the antibacterial drug in the chitosan aqueous solution, adding tricalcium phosphate, and stirring to evenly disperse the tricalcium phosphate in the solution;

[0015] (4) preparing the external aqueous phase: PVA solution;

[0016] (5) under ultrasonic dispersion conditions, mixing the inner aqueous phase into the organic phase to prepare a W / O primary emulsion;

[0017] (6) under mechanical stirring conditions, dispersing the W / O primary emulsion into the external aqueous phase to obtain a W / O / W double emulsion, standing overnight to evaporate the organic solvent, collecting the precipitate by centrifugation, washing, and freeze-drying to obtain antibacterial microbubbles;

[0018] (7) Transfer the antibacterial microbubbles to a vial covered with a rubber stopper, place the vial in a ventilation device, use a vacuum pump to completely extract the air from the vial, and inject C 3 F 8 Gas, place the vial on a silver-mercury capsule mixer and oscillate to obtain ultrasound-responsive antibacterial microbubbles.

[0019] Furthermore, the specific preparation method of the mPEG-b-(PCL-co-PLA) copolymer in step (1) is: adding caprolactone, lactide, methoxy poly(ethylene glycol) and a catalyst to dried toluene, heating to 110-120°C under vacuum conditions for reaction for 24 hours, dissolving the reaction product in dichloromethane after the reaction, using ethanol for precipitation, and purifying the product by repeated dissolution and precipitation to finally obtain the mPEG-b-(PCL-co-PLA) copolymer.

[0020] Further, the molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is (1-5):(1-5):(0.01-0.1):(0.005-0.01).

[0021] Furthermore, the catalyst is stannous octoate.

[0022] Furthermore, in step (2), the mass concentration of the mPEG-b-(PCL-co-PLA) copolymer is 10-20 mg / mL; and the amount of distearoylphosphatidylcholine added is 1-3% of the weight of the mPEG-b-(PCL-co-PLA) copolymer.

[0023] Furthermore, the antibacterial drug in step (3) is a water-soluble antibacterial drug, and the concentration of the antibacterial drug is 1-10 mg / mL.

[0024] Furthermore, the chitosan aqueous solution in step (3) also contains acetic acid with a concentration of 0.1%.

[0025] Furthermore, the concentration of tricalcium phosphate in step (3) is 1-20 mg / mL.

[0026] Furthermore, in step (4), the mass concentration of the external aqueous phase PVA solution is 3-6%.

[0027] Furthermore, in step (5), the volume ratio of the inner aqueous phase to the outer aqueous phase is 1:(8-12).

[0028] Furthermore, the present invention also discloses ultrasound-responsive antibacterial microbubbles prepared by the above method.

[0029] Beneficial effects of the present invention:

[0030] 1. The ultrasound-responsive antibacterial microbubbles prepared by the method of the present invention through emulsification and solvent evaporation have good structural stability and can remain stable in the in vivo environment, ensuring that the drug can be effectively released when needed. The addition of tricalcium phosphate enhances the responsiveness of the antibacterial microbubbles under ultrasound and improves the release efficiency of the drug.

[0031] 2. The mPEG-b-(PCL-co-PLA) copolymer and chitosan used in the method of the present invention are both known biocompatible materials that can be safely used in vivo and reduce the risk of immune response and toxicity.

[0032] 3. In the mPEG-b-(PCL-co-PLA) copolymer, mPEG provides hydrophilicity, while PCL and PLA provide hydrophobicity, which makes the copolymer have good interfacial properties and improves the stability during the emulsification process. At the same time, the ratio of PCL and PLA can adjust the degradation rate of the copolymer. The ratio of the two can be designed according to the treatment needs to ensure the stability before release and the degradation rate of the copolymer in the body after release.

[0033] 4. The chitosan used in the method of the present invention has good antibacterial properties and can synergize with antibacterial drugs to enhance the antibacterial effect; there is an obvious interaction between tricalcium phosphate and antibacterial drugs, and it has a good adsorption capacity for drugs, which significantly increases the drug loading capacity of the microbubbles. DETAILED DESCRIPTION

[0034] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments, but the protection scope of the present invention is not limited to the following embodiments.

[0035] The antibacterial drug used in the examples and comparative examples of the present invention is erythromycin;

[0036] The molecular weight of caprolactone is 800;

[0037] The molecular weight of lactide is 800;

[0038] The molecular weight of methoxypoly(ethylene glycol) is 2000.

[0039] Example 1

[0040] A method for preparing ultrasound-responsive antibacterial microbubbles comprises the following steps:

[0041] (1) Preparation of mPEG-b-(PCL-co-PLA) copolymer: Caprolactone, lactide, methoxypoly(ethylene glycol) and stannous octoate were added to dried toluene and heated to 110-120°C under vacuum conditions for reaction for 24 hours. After the reaction, the reaction product was dissolved in dichloromethane and precipitated with ethanol. The product was purified by repeated dissolution and precipitation to finally obtain mPEG-b-(PCL-co-PLA) copolymer.

[0042] The molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is 2:1:0.02:0.005.

[0043] (2) preparing the organic phase: dissolving the mPEG-b-(PCL-co-PLA) copolymer in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly;

[0044] The mass concentration of the mPEG-b-(PCL-co-PLA) copolymer is 15 mg / mL; and the amount of distearoylphosphatidylcholine added is 2% of the weight of the mPEG-b-(PCL-co-PLA) copolymer.

[0045] (3) preparing the inner aqueous phase: dissolving the antibacterial drug in the chitosan aqueous solution, adding tricalcium phosphate, and stirring to evenly disperse the tricalcium phosphate in the solution;

[0046] The antibacterial drug is a water-soluble antibacterial drug, and the concentration of the antibacterial drug is 5 mg / mL; the chitosan aqueous solution also contains acetic acid with a concentration of 0.1%; and the concentration of tricalcium phosphate is 15 mg / mL.

[0047] (4) Preparation of external aqueous phase: The mass concentration of the external aqueous phase PVA solution is 5%;

[0048] (5) Under ultrasonic dispersion conditions, the inner aqueous phase was mixed into the organic phase to prepare a W / O primary emulsion, wherein the volume ratio of the inner aqueous phase to the outer aqueous phase was 1:10;

[0049] (6) under mechanical stirring conditions, dispersing the W / O primary emulsion into the external aqueous phase to obtain a W / O / W double emulsion, standing overnight to evaporate the organic solvent, collecting the precipitate by centrifugation, washing, and freeze-drying to obtain antibacterial microbubbles;

[0050] (7) Transfer the antibacterial microbubbles to a vial covered with a rubber stopper, place the vial in a ventilation device, use a vacuum pump to completely extract the air from the vial, and inject C 3 F 8 Gas, place the vial on a silver-mercury capsule mixer and oscillate to obtain ultrasound-responsive antibacterial microbubbles.

[0051] Example 2

[0052] A method for preparing ultrasound-responsive antibacterial microbubbles comprises the following steps:

[0053] (1) Preparation of mPEG-b-(PCL-co-PLA) copolymer: Caprolactone, lactide, methoxypoly(ethylene glycol) and stannous octoate were added to dried toluene and heated to 110-120°C under vacuum conditions for reaction for 24 hours. After the reaction, the reaction product was dissolved in dichloromethane and precipitated with ethanol. The product was purified by repeated dissolution and precipitation to finally obtain mPEG-b-(PCL-co-PLA) copolymer.

[0054] The molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is 1:1:0.01:0.005.

[0055] The remaining steps are the same as in Example 1.

[0056] Example 3

[0057] A method for preparing ultrasound-responsive antibacterial microbubbles comprises the following steps:

[0058] (1) Preparation of mPEG-b-(PCL-co-PLA) copolymer: Caprolactone, lactide, methoxypoly(ethylene glycol) and stannous octoate were added to dried toluene and heated to 110-120°C under vacuum conditions for reaction for 24 hours. After the reaction, the reaction product was dissolved in dichloromethane and precipitated with ethanol. The product was purified by repeated dissolution and precipitation to finally obtain mPEG-b-(PCL-co-PLA) copolymer.

[0059] The molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is 1:2:0.02:0.005.

[0060] (2) preparing the organic phase: dissolving the mPEG-b-(PCL-co-PLA) copolymer in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly;

[0061] The mass concentration of the mPEG-b-(PCL-co-PLA) copolymer is 15 mg / mL; and the amount of distearoylphosphatidylcholine added is 2% of the weight of the mPEG-b-(PCL-co-PLA) copolymer.

[0062] (3) preparing the inner aqueous phase: dissolving the antibacterial drug in the chitosan aqueous solution, adding tricalcium phosphate, and stirring to evenly disperse the tricalcium phosphate in the solution;

[0063] The antibacterial drug is a water-soluble antibacterial drug, and the concentration of the antibacterial drug is 10 mg / mL; the chitosan aqueous solution also contains acetic acid with a concentration of 0.1%; and the concentration of tricalcium phosphate is 20 mg / mL.

[0064] (4) Preparation of external aqueous phase: The mass concentration of the external aqueous phase PVA solution is 5%;

[0065] (5) Under ultrasonic dispersion conditions, the inner aqueous phase was mixed into the organic phase to prepare a W / O primary emulsion, wherein the volume ratio of the inner aqueous phase to the outer aqueous phase was 1:10;

[0066] (6) under mechanical stirring conditions, dispersing the W / O primary emulsion into the external aqueous phase to obtain a W / O / W double emulsion, standing overnight to evaporate the organic solvent, collecting the precipitate by centrifugation, washing, and freeze-drying to obtain antibacterial microbubbles;

[0067] (7) Transfer the antibacterial microbubbles to a vial covered with a rubber stopper, place the vial in a ventilation device, use a vacuum pump to completely extract the air from the vial, and inject C 3 F 8 Gas, place the vial on a silver-mercury capsule mixer and oscillate to obtain ultrasound-responsive antibacterial microbubbles.

[0068] Comparative Example 1

[0069] A method for preparing ultrasound-responsive antibacterial microbubbles comprises the following steps:

[0070] (1) preparing the organic phase: dissolving PCL in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly;

[0071] The mass concentration of PCL is 15 mg / mL; and the added amount of distearoylphosphatidylcholine is 2% of the weight of PCL.

[0072] The remaining steps are the same as in Example 1.

[0073] Comparative Example 2

[0074] A method for preparing ultrasound-responsive antibacterial microbubbles comprises the following steps:

[0075] (1) Preparation of mPEG-b-(PCL-co-PLA) copolymer: Caprolactone, lactide, methoxypoly(ethylene glycol) and stannous octoate were added to dried toluene and heated to 110-120°C under vacuum conditions for reaction for 24 hours. After the reaction, the reaction product was dissolved in dichloromethane and precipitated with ethanol. The product was purified by repeated dissolution and precipitation to finally obtain mPEG-b-(PCL-co-PLA) copolymer.

[0076] The molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is 2:1:0.02:0.005.

[0077] (2) preparing the organic phase: dissolving the mPEG-b-(PCL-co-PLA) copolymer in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly;

[0078] The mass concentration of the mPEG-b-(PCL-co-PLA) copolymer is 15 mg / mL; and the amount of distearoylphosphatidylcholine added is 2% of the weight of the mPEG-b-(PCL-co-PLA) copolymer.

[0079] (3) preparing the inner water phase: dissolving the antibacterial drug in water, adding tricalcium phosphate, and stirring to evenly disperse the tricalcium phosphate in the solution;

[0080] Among them, the antibacterial drug is a water-soluble antibacterial drug, and the concentration of the antibacterial drug is 5 mg / mL; the concentration of tricalcium phosphate is 15 mg / mL.

[0081] The remaining steps are the same as in Example 1.

[0082] Comparative Example 3

[0083] (1) Preparation of mPEG-b-(PCL-co-PLA) copolymer: Caprolactone, lactide, methoxypoly(ethylene glycol) and stannous octoate were added to dried toluene and heated to 110-120°C under vacuum conditions for reaction for 24 hours. After the reaction, the reaction product was dissolved in dichloromethane and precipitated with ethanol. The product was purified by repeated dissolution and precipitation to finally obtain mPEG-b-(PCL-co-PLA) copolymer.

[0084] The molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is 2:1:0.02:0.005.

[0085] (2) preparing the organic phase: dissolving the mPEG-b-(PCL-co-PLA) copolymer in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly;

[0086] The mass concentration of the mPEG-b-(PCL-co-PLA) copolymer is 15 mg / mL; and the amount of distearoylphosphatidylcholine added is 2% of the weight of the mPEG-b-(PCL-co-PLA) copolymer.

[0087] (3) preparing the inner aqueous phase: dissolving the antimicrobial drug in the chitosan aqueous solution;

[0088] The antibacterial drug is a water-soluble antibacterial drug, and the concentration of the antibacterial drug is 5 mg / mL; the chitosan aqueous solution also contains acetic acid with a concentration of 0.1%.

[0089] The remaining steps are the same as in Example 1.

[0090] Comparative Example 4

[0091] (1) Preparation of mPEG-b-(PCL-co-PLA) copolymer: Caprolactone, lactide, methoxypoly(ethylene glycol) and stannous octoate were added to dried toluene and heated to 110-120°C under vacuum conditions for reaction for 24 hours. After the reaction, the reaction product was dissolved in dichloromethane and precipitated with ethanol. The product was purified by repeated dissolution and precipitation to finally obtain mPEG-b-(PCL-co-PLA) copolymer.

[0092] The molar ratio of caprolactone, lactide, methoxy poly(ethylene glycol) and catalyst is 2:1:0.005:0.005.

[0093] The remaining steps are the same as in Example 1.

[0094] Test Example 1

[0095] Stability test of ultrasound-responsive antibacterial microbubbles

[0096] 50 mg of the antibacterial microbubbles in Examples 1-3 and Comparative Examples 1-4 were dispersed in 50 mL of PBS buffer, divided into sample chambers, and incubated in a 37°C incubator. Three parallel samples were taken out every 7 d, 14 d, 21 d, and 28 d. Ultrasonic imaging of the microbubbles was performed by an ultrasonic diagnostic apparatus in a pre-degassed water bath. The average signal intensity of the microbubbles in the specified area of ​​the obtained ultrasonic development image was analyzed by Image J software. The analysis results are shown in Table 1. The data in Table 1 are the microbubble ultrasonic imaging signal intensities in dB.

[0097] Table 1

[0098] Group 0d 7d 14d 21d 28d Example 1 23.7 24.4 23.9 25.7 25.3 Example 2 22.9 23.5 24.1 23.9 24.8 Example 3 23.4 24.6 24.0 25.2 24.9 Comparative Example 1 25.9 18.9 9.1 1.5 0 Comparative Example 2 24.6 22.5 20.6 17.9 14.2 Comparative Example 3 24.5 23.1 22.6 24.8 24.3 Comparative Example 4 24.1 20.9 16.8 11.9 5.2

[0099] As can be seen from the results in Table 1, in the continuous 28d incubation, the intensity of the ultrasonic imaging signal of the microbubbles obtained in Examples 1-3 did not change significantly compared with before incubation. The ultrasonic signal of the microbubbles was generated by the gas encapsulated in the microbubbles vibrating under the action of ultrasound. The ultrasonic signal of the microbubbles was stable, indicating that the gas encapsulated by the microbubbles still existed stably without escaping, and the stability of the microbubble structure could be judged. In Comparative Example 1, PCL was directly used as the organic phase to prepare microbubbles. The PCL in the prepared microbubbles was strongly hydrophobic and lacked interaction with the inner aqueous phase, and the stability of the microbubbles could not be maintained for a long time. In Comparative Example 2, the inner aqueous phase did not contain chitosan, and the chitosan solution provided a rich group that could interact with the mPEG-b-(PCL-co-PLA) copolymer in the organic phase to form a self-stabilizing system, which could maintain the stability of the microbubbles for a long time, and the stability of the microbubbles without adding chitosan decreased. In Comparative Example 4, the content of mPEG in the mPEG-b-(PCL-co-PLA) copolymer was reduced, the polyethylene glycol segment of mPEG introduced into the mPEG-b-(PCL-co-PLA) copolymer was reduced, and the hydrophilicity of the mPEG-b-(PCL-co-PLA) copolymer was reduced, resulting in a decrease in the stability of the microbubbles, but the overall stability was higher than that in Comparative Example 1.

[0100] Test Example 2

[0101] Calculation of ultrasound-responsive microbubble encapsulation rate: accurately weigh 50 mg of ultrasound-responsive microbubbles and dissolve them in 1 mL of chloroform. Use 1 mL of ultrapure water to extract erythromycin. After centrifugation at room temperature, aspirate the supernatant and determine the concentration of erythromycin in the supernatant by high performance liquid chromatography. Calculate the encapsulation rate of ultrasound-responsive microbubbles, encapsulation rate = actual drug loading rate / theoretical drug loading rate*100%.

[0102] The encapsulation efficiency of ultrasound-responsive microbubbles in Examples 1-3 was finally calculated to be 69.22%, 67.57% and 68.91%, respectively. The encapsulation efficiency of ultrasound-responsive microbubbles in Comparative Example 1 was 43.37%, because PCL is highly hydrophobic and lacks the ability to stabilize the emulsion. When encapsulating drugs, the emulsion is prone to phase separation, causing a large amount of drug leakage, resulting in a low encapsulation efficiency of microbubbles. The encapsulation efficiency of ultrasound-responsive microbubbles in Comparative Example 2 was 55.68%, because chitosan can interact with the mPEG-b-(PCL-co-PLA) copolymer in the organic phase to form a self-stabilizing system. Without adding chitosan, phase separation also occurs when encapsulating drugs. The encapsulation efficiency of ultrasound-responsive microbubbles in Comparative Example 3 was 38.96%, because there was an obvious interaction force between tricalcium phosphate and antibacterial drugs, and it had good adsorption capacity for drugs. Without adding tricalcium phosphate, the encapsulation efficiency of microbubbles was significantly reduced. The encapsulation efficiency of ultrasound-responsive microbubbles in Comparative Example 4 was 60.52%.

[0103] Test Example 3

[0104] In vitro ultrasonic drug release test: 50 mg of ultrasonic responsive microbubbles were accurately weighed and dispersed in 10 mL of normal saline. After constant temperature shaking at 37 ° C and 100 rpm for 2 h, an ordinary ultrasonic diagnostic instrument was used for ultrasonic treatment at 90 s / time. After ultrasonic treatment, 1 mL of the sample was immediately dissolved in 1 mL of chloroform, and erythromycin was extracted with 1 mL of ultrapure water. After centrifugation at room temperature, the supernatant was aspirated, and the concentration of erythromycin in the supernatant was determined by high performance liquid chromatography. According to the concentration of erythromycin in the supernatant, the cumulative amount of in vitro ultrasonic drug release was calculated. The drug release rate in Example 1 reached 43.21%, and the drug release rate in Comparative Example 3 was 34.65%. It can be seen that the addition of tricalcium phosphate enhances the responsiveness of the antibacterial microbubbles under ultrasonic action and improves the release efficiency of the drug.

[0105] Finally, it should be noted that the above-mentioned embodiments only express several implementation methods of the present invention and are not intended to limit the invention. For ordinary technicians in this field, any modifications, equivalent substitutions, improvements, etc. made without departing from the concept of the present invention should be included in the protection scope of the invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.

Claims

1. A method for preparing ultrasound-responsive antibacterial microbubbles, characterized in that: The following steps are involved: (1) mPEG-b-(PCL-co-PLA) copolymers were prepared using caprolactone and lactide as monomers and methoxy poly(ethylene glycol) as initiator; (2) preparing the organic phase: dissolving the mPEG-b-(PCL-co-PLA) copolymer in dichloromethane, adding distearoylphosphatidylcholine after it is completely dissolved and mixing evenly; (3) preparing the inner aqueous phase: dissolving the antibacterial drug in the chitosan aqueous solution, adding tricalcium phosphate, and stirring to evenly disperse the tricalcium phosphate in the solution; (4) preparing the external aqueous phase: PVA solution; (5) under ultrasonic dispersion conditions, mixing the inner aqueous phase into the organic phase to prepare a W / O primary emulsion; (6) under mechanical stirring conditions, dispersing the W / O primary emulsion into the external aqueous phase to obtain a W / O / W double emulsion, standing overnight to evaporate the organic solvent, collecting the precipitate by centrifugation, washing, and freeze-drying to obtain antibacterial microbubbles; (7) The antibacterial microbubbles are transferred to a vial covered with a rubber stopper, the vial is placed in a ventilation device, the air in the vial is completely extracted with a vacuum pump, C3F8 gas is injected, and the vial is placed on a silver-mercury capsule mixer for oscillation to obtain ultrasound-responsive antibacterial microbubbles.

2. The preparation method according to claim 1, characterized in that: The specific preparation method of the mPEG-b-(PCL-co-PLA) copolymer in step (1) is as follows: caprolactone, lactide, methoxy poly(ethylene glycol) and a catalyst are added to dried toluene, heated to 110-120°C under vacuum conditions for reaction for 24 hours, and after the reaction is completed, the reaction product is dissolved in dichloromethane, precipitated with ethanol, and the product is purified by repeated dissolution and precipitation to finally obtain the mPEG-b-(PCL-co-PLA) copolymer.

3. The preparation method according to claim 2, characterized in that: The molar ratio of caprolactone, lactide, methoxypoly(ethylene glycol) and catalyst is (1-5):(1-5):(0.01-0.1):(0.005-0.01).

4. The preparation method according to claim 2, characterized in that: The catalyst is stannous octoate.

5. The preparation method according to claim 1, characterized in that: The mass concentration of the mPEG-b-(PCL-co-PLA) copolymer in step (2) is 10-20 mg / mL; the amount of distearoylphosphatidylcholine added is 1-3% of the weight of the mPEG-b-(PCL-co-PLA) copolymer.

6. The preparation method according to claim 1, characterized in that: The antibacterial drug in step (3) is a water-soluble antibacterial drug, and the concentration of the antibacterial drug is 1-10 mg / mL.

7. The preparation method according to claim 1, characterized in that: The concentration of tricalcium phosphate in step (3) is 1-20 mg / mL.

8. The preparation method according to claim 1, characterized in that: The mass concentration of the external aqueous phase PVA solution in step (4) is 3-6%.

9. The preparation method according to claim 1, characterized in that: In step (5), the volume ratio of the inner water phase to the outer water phase is 1:(8-12).

10. Ultrasound-responsive antibacterial microbubbles prepared by the method according to any one of claims 1 to 9.

Citation Information

Cited By

  • Injectable polyester polymer / beta-tricalcium phosphate composite microsphere as well as preparation method and application thereof

    CN119971135A